A report by GTRI highlights that former US President Trump's proposed tariffs of up to 200% on imported generic drugs could significantly impact India's .
200%
Proposed Tariff Rate
📊 One chart explains it
India's Pharmaceutical Exports to the US
Takeaway: India's pharmaceutical exports to the US have shown consistent growth, making them highly vulnerable to new tariffs.
⏳ Time Machine
How today’s news fits into the bigger picture
1970s
Indian Patent Act of 1970
This act allowed process patents but not product patents for drugs, enabling Indian companies to reverse-engineer and produce affordable generic versions of patented medicines, laying the foundation for India's generic drug industry.
2005
WTO-compliant Patent Act
India amended its Patent Act to become WTO-compliant, recognizing product patents for pharmaceuticals. However, Indian companies had already built significant capabilities in generic drug manufacturing by this point.
2008-2016
Rise of Indian pharma in US market
Indian pharmaceutical companies significantly expanded their presence in the US market, becoming major suppliers of generic drugs and contributing to lower healthcare costs for American consumers.
2018
Trump's initial trade protectionism
During his previous presidency, Donald Trump initiated several protectionist trade policies, including tariffs on steel and aluminum, signaling a broader shift towards 'America First' economic policies.
Today
GTRI released a report highlighting the severe potential impact of former US President Trump's proposed 200% tariffs on Indian generic drug exports.
What happens next?
The Indian government and pharmaceutical industry will likely engage in diplomatic efforts with the US to negotiate or mitigate the proposed tariffs, while companies may explore market diversification strategies.
A recent report by the Global Trade Research Initiative (GTRI) warns that former US President Donald Trump's proposal to impose tariffs of up to **200%** on imported generic medicines by 2028 would have a significant negative impact on India. India is the world's largest supplier of generic drugs and a major exporter to the United States. These proposed tariffs aim to boost domestic drug manufacturing in the US, but could lead to higher costs for American consumers and severely disrupt India's pharmaceutical export economy, especially for higher-value generic formulations.
💭 If you're wondering…
A generic drug is a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. They are typically much cheaper.
Did this story help?
Official sources
Knowledge Chain — tap a concept